Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review.European journal of clinical pharmacology · 2026
   Pooled it
2. The life cycle of the alphaviruses: From an antiviral perspective.Antiviral research · 2023
   Pooled it
3. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.Microorganisms · 2024
   Review
4. Vitamin D Fortification: A Promising Approach to Overcome Drug Resistance and Tolerance in Therapeutic Interventions.Scientifica · 2024
   Review
5. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.Diagnostics (Basel, Switzerland) · 2023
   Article
6. Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).Expert review of anti-infective therapy · 2022
   Review
7. Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022
   Article
8. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study.Journal of pharmaceutical policy and practice · 2021
   Review
9. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.Expert opinion on pharmacotherapy · 2021
   Review
10. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.mBio · 2021
    Article
11. Generation of Combinatorial Lentiviral Vectors Expressing Multiple Anti-Hepatitis C Virus shRNAs and Their Validation on a Novel HCV Replicon Double Reporter Cell Line.Viruses · 2020
    Article
12. HCV genotypes and their determinative role in hepatitis C treatment.Virusdisease · 2020
    Review
13. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
14. Minimizing Risks Is Not Enough: The Relevance of Benefits to Protecting Research Participants.Perspectives in biology and medicine · 2020
    Article
15. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.Current gastroenterology reports · 2019
    Review
16. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.Antimicrobial agents and chemotherapy · 2019
    Article
17. Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.Hepatology communications · 2019
    Article
18. Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy.Viruses · 2019
    Review
19. Hepatitis C Pretreatment Profile and Gender Differences: Cognition and Disease Severity Effects.Frontiers in psychology · 2019
    Article
20. Methanolic Extract ofViruses · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract